Key Takeaways
- Clinical Bottom Line
- Ending the Lifelong Pill
Clinical Bottom Line
| Hepatitis B Therapy | Therapeutic Target | Clinical Endpoint |
|---|---|---|
| Nucleotide Analogs (Tenofovir) | Suppresses viral replication (HBV DNA). | Requires lifelong adherence; viral rebound occurs immediately upon cessation. |
| Novel siRNA Therapies | Physically degrades the viral mRNA sequence inside the liver cell. | Targeting “Functional Cure”—loss of HBsAg with sustained undetectable DNA. |
Ending the Lifelong Pill
For decades, managing Chronic Hepatitis B (CHB) was a strategy of “containment,” not eradication. Patients were placed on daily oral Tenofovir or Entecavir to suppress viral loads and prevent cirrhosis, with the expectation that they would never be able to stop the medication. The EASL 2025-2026 guidelines denote a radical pivot toward “Functional Cure.”
The siRNA Breakthrough
Newer small-interfering RNA (siRNA) therapies actually enter the hepatocyte and neutralize the viral machinery responsible for producing the Hepatitis B Surface Antigen (HBsAg). By depleting HBsAg, the body’s native immune system “wakes up” and begins to actively clear the remaining infection. Achieving a high rate of HBsAg loss in recent clinical trials suggests that within the next 5 years, we will shift from lifelong viral suppression to finite, 12-month curative injections for the millions of patients currently tethered to daily oral antivirals.
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: 2026. This article is intended for physicians.
